Pumitamig Plus Chemo Yields Promising Results in Early Data

In an interview at the 2025 San Antonio Breast Cancer Symposium, Peter Schmid, MD, PhD, Barts Cancer Institute in London, England, discussed the preliminary data from a global multicohort phase 2 randomized trial of pumitamig plus chemotherapy for patients with locally advanced/metastatic triple negative breast cancer.

Schmid detailed the rationale of combining pumitamig and chemotherapy and how the combination can aid patients in the first or second-line setting. Schmid noted that confirmed responses are approximately 62%, and the unconfirmed responses are approximately 72%.